Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Enforcement in Brief

This article was originally published in The Gold Sheet

Executive Summary

FDA and PIC/S inspection approaches are evolving, with FDA focusing on beta-lactams, CMOs and contract labs; and PIC/S working on inspection sharing, harmonizing on deficiencies, data integrity guidance and inspector training. Meanwhile, Dr Reddy’s gets warning letter, AstraZeneca sees EU noncompliance and four firms added to FDA’s drug GMP import alert.


Related Content

GSK Faces 'Profoundly Difficult' Penicillin Challenge, FDA Warning Letter Says





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts